Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating

Olema Pharmaceuticals (NASDAQ:OLMA) is one of the 17 biotechnology stocks with more than 50% upside.

On February 11, Laura Prendergast of Stifel Nicolaus initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA). She assigned a Buy rating to the stock with a $48 price target, which leads to more than 102% upside potential for investors.

Using a conservative approach, Prendergast has modeled peak sales for palazestrant at $3.1 billion in 2035. She also noted that endocrine therapy in ER+HER2 can be “a $20B+ global market opportunity with plenty of room for many big players.”

On January 7, Michael Yee of UBS also initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA), assigning a Buy rating and a $48 price target. He based his rating on a more favorable outlook for the biotech segment after what he described as a “rough period.” Yee expects greater investor confidence in the segment, which should drive better performance in 2026.

Olema Pharmaceuticals (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for women’s cancers. They commercialize next-gen breast cancer therapies, particularly targeting ER+/HER2- cancer. Its lead program is Palazestrant (OP-1250) to cure metastatic breast cancer, which is currently in Phase 3 clinical trials.

While we acknowledge the potential of OLMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.